BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND TG, Thyroglobulin AND Treatment
1575 results:

  • 1. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
    Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
    Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
    Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
    BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. False diagnosis of recurrent thyroid carcinoma: the importance of testing for heterophile antibodies.
    Guastapaglia L; Chiamolera MI; Viana Lima Junior J; Ferrer CMF; Godoy Viana L; Veiga Chang C; Andrade Siqueira R; Monteiro Barros Maciel R; Henriques Vieira JG; Biscolla RPM
    Arch Endocrinol Metab; 2024 Mar; 68():e230115. PubMed ID: 38456952
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid cancer.
    Sun D; Zhang X; Sun Y; Mu Z; Wang H; Zhang Y; Liang J; Lin Y
    Endocr Pract; 2024 May; 30(5):456-464. PubMed ID: 38447630
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients.
    Chantadisai M; Wongwijitsook J; Ritlumlert N; Rakvongthai Y
    Sci Rep; 2024 Feb; 14(1):5001. PubMed ID: 38424177
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
    Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Correlation between remnant thyroid gland I-131 uptake and serum thyroglobulin levels: can we rely on I-131 whole body scans?
    Hwang SH; Jo K; Cha J; Kang CG; Wang J; Cho H; Kang WJ; Cho A
    Cancer Imaging; 2024 Jan; 24(1):21. PubMed ID: 38291522
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer.
    Watanabe K; Igarashi T; Uchiyama M; Ishigaki T; Ojiri H
    Jpn J Radiol; 2024 Apr; 42(4):391-397. PubMed ID: 38212512
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid cancer in the West of Scotland: A Retrospective Analysis.
    Graham K; Tough F; Belikova H; Wotherspoon I; Colville D; Reed N
    Endocr Pract; 2024 Apr; 30(4):327-332. PubMed ID: 38184240
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Applying Untargeted Lipidomics to Evaluate the Efficacy of Combined Neoadjuvant Chemotherapy and Immunotherapy for Esophageal Squamous Carcinoma treatment.
    Lin W; Si X; Zhao Z; Chen F; Xu J; Huang W; Lin J; Chen Z; Huang Z
    J Proteome Res; 2024 Feb; 23(2):663-672. PubMed ID: 38175711
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
    Altan M; Li QZ; Wang Q; Vokes NI; Sheshadri A; Gao J; Zhu C; Tran HT; Gandhi S; Antonoff MB; Swisher S; Wang J; Byers LA; Abdel-Wahab N; Franco-Vega MC; Wang Y; Lee JJ; Zhang J; Heymach JV
    Front Immunol; 2023; 14():1322818. PubMed ID: 38152395
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Risk factors for recurrence of differentiated thyroid carcinoma in children and adolescents: A retrospective cohort study.
    Jia S; Tang D; Peng W
    Medicine (Baltimore); 2023 Dec; 102(50):e36585. PubMed ID: 38115329
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Surgical outcomes of endoscopic thyroidectomy approaches for thyroid cancer: a systematic review and network meta-analysis.
    Li X; Ding W; Zhang H
    Front Endocrinol (Lausanne); 2023; 14():1256209. PubMed ID: 38111707
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Radioactive iodine therapy for follicular thyroid cancer: a 15 years follow-up study of Chinese patients.
    Shi H; Yang B; Feng JI; Li JH; Cheng X; Li YJ; Fu Y; Xu XD; Qian LH; Tang LJ; Liu W
    Nucl Med Commun; 2024 Mar; 45(3):169-174. PubMed ID: 38095140
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The Prognostic Power of Preablation Stimulated thyroglobulin in Children With Differentiated Thyroid cancer.
    Nesari Javan F; Askari E; Shafiei S; Roshanravan V; Aghaei A; Ayati N; Zakavi SR
    Endocr Pract; 2024 Mar; 30(3):209-217. PubMed ID: 38092290
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Constructing a nomogram based on the distribution of thyroid nodules and suspicious lateral cervical lymph nodes in fine-needle aspiration biopsies to predict metastasis in papillary thyroid carcinoma.
    Liu SQ; Feng JW; Yan ZT; Xing XX; Jiang WY; Jiang Y; Qian F; Xing W
    Front Endocrinol (Lausanne); 2023; 14():1242061. PubMed ID: 38089614
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Wire-guided localization and surgical resection of non-palpable recurrent of thyroid carcinoma: A STROBE-compliant, retrospective cohort study.
    Carrillo JF; Carrillo LC; Ramírez-Ortega MC; Pacheco-Bravo I; Ramos-Mayo A; Oñate-Ocaña LF
    Eur J Surg Oncol; 2024 Jan; 50(1):107306. PubMed ID: 38048725
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
    Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
    Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Challenges and current advances in the methodology of thyroglobulin measurements.
    Đorić I; Šelemetjev S
    Bioanalysis; 2024 Jan; 16(1):49-60. PubMed ID: 37991211
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 79.